Freestone Grove Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Freestone Grove Partners’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.39M	Sell	101,332 -152,898	-60%	-$12.3M	0.05%	307
2026 Q1	$19.6M	Buy	254,230 +113,121	+80%	+$8.83M	0.14%	212
2025 Q4	$11.1M	Buy	141,109 +110,425	+360%	+$9.56M	0.08%	279
2025 Q3	$2.81M	Sell	30,684 -164,530	-84%	-$13.4M	0.02%	355
2025 Q2	$12.7M	Buy	195,214 +191,217	+4,784%	+$12.4M	0.1%	254
2025 Q1	$268K	Sell	3,997 -682	-15%	-$40.7K	﹤0.01%	494
2024 Q4	$259K	Buy	+4,679	New	+$269K	﹤0.01%	492

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's ANIP Position: Q2 2026 in Review

Freestone Grove Partners reduced its ANI Pharmaceuticals (ANIP) stake by 60% in Q2 2026, selling an estimated $12.3M and leaving 101,332 shares worth $8.39M. The position accounts for 0.05% of the portfolio, ranked #307.

Freestone Grove Partners first reported a position in ANIP in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.6M in Q1 2026. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Freestone Grove Partners held 101,332 shares of ANI Pharmaceuticals worth $8.39M as of Q2 2026.
Freestone Grove Partners sold 152,898 ANI Pharmaceuticals shares in Q2 2026, an estimated $12.3M.
ANI Pharmaceuticals made up 0.05% of Freestone Grove Partners's portfolio in Q2 2026, its #307 holding.
Freestone Grove Partners first reported a position in ANI Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Freestone Grove Partners's ANI Pharmaceuticals position peaked at $19.6M in Q1 2026.
308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.